BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up - What's Next?

Key Points

• BlossomHill Therapeutics shares gapped higher, opening at $21.17 versus a prior close of $19.75 and last trading at $21.27.
• Analyst sentiment is broadly positive: five analysts rate the stock Buy and one rates it Hold, producing a “Moderate Buy” consensus and a $35 average price target.
• The company reported a substantial quarterly loss of $8.75 per share, far below the $0.84 consensus estimate, though insiders have purchased 1.57 million shares worth about $25.2 million over the past 90 days.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $19.75, but opened at $21.17. BlossomHill Therapeutics shares last traded at $21.27, with a volume of 10,184 shares changing hands.

Wall Street Analysts Forecast Growth

BLSM has been the subject of a number of research reports. Zacks Research upgraded shares of BlossomHill Therapeutics to a "hold" rating in a research note on Wednesday, September 2nd. HC Wainwright started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued a "buy" rating and a $35.00 target price on the stock. Wall Street Zen upgraded BlossomHill Therapeutics to a "hold" rating in a research note on Saturday, August 15th. JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an "overweight" rating and a $28.00 target price for the company. Finally, Lifesci Capital started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued an "outperform" rating and a $32.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.00.

BlossomHill Therapeutics Price Performance

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) last released its earnings results on Friday, September 18th. The company reported ($8.75) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($7.91). Analysts expect that BlossomHill Therapeutics, Inc. will post -5.54 EPS for the current year.

Insider Activity at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Carl Gordon purchased 625,000 shares of the business's stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the purchase, the director owned 2,714,279 shares of the company's stock, valued at approximately $43,428,464. This represents a 29.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Vincent Liptak acquired 2,500 shares of the stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the transaction, the general counsel directly owned 109,212 shares of the company's stock, valued at approximately $1,725,549.60. This represents a 2.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 1,573,900 shares of company stock worth $25,181,900 in the last 90 days.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.